Xie S, Qiang Q, Mei L, He C, Feng Y, Sun H, Wu X, et al.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto.... Date of publication 2018 Jan 1;volume 275(1):47-51.
1. Eur Arch Otorhinolaryngol. 2018 Jan;275(1):47-51. doi: 10.1007/s00405-017-4784-4.
Epub 2017 Oct 25.
Multivariate analysis of prognostic factors for idiopathic sudden sensorineural
hearing loss treated with adjuvant hyperbaric oxygen therapy.
Xie S(1)(2), Qiang Q(1)(2), Mei L(1)(2), He C(1)(2), Feng Y(1)(2), Sun H(1)(2),
Wu X(3)(4).
Author information:
(1)Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital Central
South University, Changsha, 410008, Hunan, China.
(2)Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Changsha,
410008, Hunan, China.
(3)Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital Central
South University, Changsha, 410008, Hunan, China. xwwu840903@hotmail.com.
(4)Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Changsha,
410008, Hunan, China. xwwu840903@hotmail.com.
The objective of this study is to evaluate possible prognostic factors of
idiopathic sudden sensorineural hearing loss (ISSNHL) treated with adjuvant
hyperbaric oxygen therapy (HBOT) using univariate and multivariate analyses. From
January 2008 to October 2016, records of 178 ISSNHL patients treated with
auxiliary hyperbaric oxygen therapy were reviewed to assess hearing recovery and
evaluate associated prognostic factors (gender, age, localization, initial
hearing threshold, presence of tinnitus, vertigo, ear fullness, hypertension,
diabetes, onset of HBOT, number of HBOT, and audiogram), by using univariate and
multivariate analyses. The overall recovery rate was 37.1%, including complete
recovery (19.7%) and partial recovery (17.4%). According to multivariate
analysis, later onset of HBOT and higher initial hearing threshold were
associated with a poor prognosis in ISSNHL patients treated with HBOT. HBOT is a
safe and beneficial adjuvant therapy for ISSNHL patients. 20 sessions of HBOT is
possibly enough to show its therapeutic effect. Earlier HBOT onset and lower
initial hearing threshold is associated with favorable hearing recovery.
DOI: 10.1007/s00405-017-4784-4
PMID: 29071444 [Indexed for MEDLINE]
